Clinical

Individuals with the same genetic mitochondrial defect can exhibit widely variable symptoms, disease severity, and ages of onset.

The World Professional Association for Transgender Health (WPATH) provides clinical practice guidelines for treating people with gender dysphoria.

Common medical interventions used in treating pediatric gender dysphoria include puberty blockers, cross-sex hormones, and gender-affirming surgeries.

Medical interventions for pediatric gender dysphoria have been associated in the literature with potential risks including infertility or sterility, sexual dysfunction, impaired bone-density accrual, adverse cognitive impacts, cardiovascular disease and metabolic disorders, psychiatric disorders, surgical complications, and regret.

Infant botulism is caused by Clostridium botulinum bacteria that form spores which can germinate in an infant's gut and produce a toxin that may lead to paralysis or death.

Symptoms of infant botulism can include constipation, poor feeding, a weak cry, drooping eyelids, a flat facial expression, weakness in the limbs and neck (a "floppy" appearance), and difficulty swallowing or breathing.

Symptoms of infant botulism can take up to 30 days to develop after exposure.

Menopause hormone therapy (also called hormone replacement therapy or HRT) comprises medications prescribed to treat menopause symptoms such as hot flashes, night sweats, mood swings, and vaginal dryness by replenishing hormones like estrogen and progesterone that decline during the transition to menopause.